Cabaletta Bio is trading 5% up at $2.89 after August 17, 2026 reports highlighted encouraging rese-cel Phase 1/2 results, including sustained responses for up to 18 months without ongoing immunomodulators.
- The update supports the company’s outpatient-development strategy and likely strengthened investor confidence in its autoimmune CAR-T program.
- August 13 earnings showed $225.1 million in liquidity, expected to fund operations into mid-2027.
- The broader market is mixed, with no major macro catalyst scheduled, making the clinical update the clearest explanation.